CStone Pharmaceuticals Co. Ltd.
http://www.cstonepharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CStone Pharmaceuticals Co. Ltd.
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
EU Crunch Time For Myriad Drugs Marks A Busy May Meeting For CHMP
The latest meeting of the European Medicines Agency’s human medicines committee, the CHMP, is taking place this week. Decisions are expected for 13 drug marketing applications, there will be a number of oral explanation meetings, and activity is expected relating to a drug at the center of a case involving the European Commission’s rejection of an EMA recommendation.
Asia Deal Watch: Ono Calls On PRISM BioLab’s Capabilities
Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.
Blueprint RETreats As It Sells US Gavreto Rights To Rigel
After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice